Loading
Giving daratumumab for up to three years to people with high-risk smouldering myeloma roughly halved the risk of progressing to active myeloma or death compared with watching and waiting.
Phase 3 trial of 390 patients with high-risk smouldering multiple myeloma randomised to subcutaneous daratumumab monotherapy for up to 36 months or active monitoring.
Five-year progression-free survival was 63.1 percent with daratumumab against 40.8 percent with monitoring (hazard ratio 0.49), with a favourable trend in overall survival and a manageable toxicity profile.
Early single-agent treatment of high-risk smouldering myeloma is now an option with regulatory approval, though monitoring remains acceptable and the definition of high risk matters.
Shares Smouldering multiple myeloma, Daratumumab.
Shares Smouldering multiple myeloma, Daratumumab.
Shares Smouldering multiple myeloma, Daratumumab.
Shares Smouldering multiple myeloma, Daratumumab.
Shares Smouldering multiple myeloma, Daratumumab.